Medifast’s OPTAVIA Trials Show 98% Lean Mass Retention and 14% Fat Loss
MED•Medifast's OPTAVIA uses DXA scanning in trials to show 98% lean mass retention and 14% visceral fat reduction in 16 weeks, with coach-supported clients losing ten times more weight than self-directed participants. The weight loss market reached $31.07 billion in 2025 and could exceed $45 billion by 2030.
1. OPTAVIA’s Clinical Trial Framework
OPTAVIA’s research portfolio is built on randomized controlled trials using dual-energy X-ray absorptiometry (DXA) to track body composition changes in 198 participants over 16 weeks. This methodology distinguishes fat mass, lean mass, and bone mineral content with greater precision than scale weight alone, ensuring verifiable outcomes.
2. Key Efficacy Outcomes
The 16-week trial reported 98% lean mass retention and a 14% reduction in visceral fat among participants. Coach-supported clients achieved ten times greater weight loss than self-directed users, highlighting the impact of personalized guidance on metabolic health results.
3. Market Opportunity
The global weight loss and diet management market reached $31.07 billion in 2025 and is projected to exceed $45 billion by 2030. Expanding demand for clinically validated, outcome-driven programs positions OPTAVIA to capture a growing share of this multibillion-dollar industry.
4. Implications for Medifast
These clinical successes reinforce Medifast’s competitive differentiation in subscription-based health programs and could drive subscriber growth and retention. Demonstrated efficacy and transparent measurement protocols may enhance investor confidence in Medifast’s scalable, science-backed model.
